semaglutide vs tirzepatide safety vs. Ozempic: Comparing Diabetes Treatments & Weight Loss Benefits Semaglutide vs. Tirzepatide for Weight

The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme demonstrated that adults using semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of approximately 15% of their body weight over 68 weeks, compared to around 2.4% with placebo. NICE approved Wegovy for use in specialist weight management services in the UK in 2023 (TA875), recognising its clinical effectiveness. Ongoing research continues to explore its cardiovascular benefits, with the SELECT trial showing a significant reduction in major cardiovascular events in people with obesity

Compare their effectiveness, safety, and availability to see which option works better for you.

When considering weight loss medications, many people wonder about the differences between semaglutide and tirzepatide.

When weight struggles are misread as laziness, shame compounds, motivation collapses, and the cycle tightens

Obesity is a growing global health concern that leads to metabolic imbalances and progressive cardiac remodelling

Methods Data were obtained from trials with subcutaneous and intravenous administration of semaglutide that utilised frequent PK sampling and included a total of 353 subjects with 10,573 concentration values